Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications

Seminars in Oncology

Volumn 36, Issue SUPPL. 2, 2009, Pages

  Pui, Ching Hon ^a   Thiel, Eckhard ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE SODIUM SUCCINATE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; THIOTEPA; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARACHNOIDITIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLINDNESS; BRAIN DISEASE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RELAPSE; CANCER SURVIVAL; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CHILD; CLINICAL TRIAL; CONFUSION; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPONATREMIA; INTRACRANIAL PRESSURE; LIVER TOXICITY; LYMPHOBLASTOMA; MENINGISM; MENINGITIS; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLEDEMA; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SEIZURE; SIDE EFFECT; SKULL IRRADIATION; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; VEIN OCCLUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, NON-HODGKIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 67849094665     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.05.002     Document Type: Article

References (107)

1. Simone J.V. History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol 19 (2006) 353-359
2. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
3. Pui C.H., and Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9 (2008) 257-268
4. Glantz M.J., Cole B.F., Glantz L.K., Cobb J., Mills P., Lekos A., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82 (1998) 733-739
5. Zeiser R., Burger J.A., Bley T.A., Windfuhr-Blum M., Schulte-Monting J., and Behringer D.M. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis-a single centre experience. Br J Haematol 124 (2004) 762-768
6. Phillips M.E., Ryals T.J., Kambhu S.A., and Yuh W.T. Neoplastic vs inflammatory meningeal enhancement with Gd-DTPA. J Comput Assist Tomogr 14 (1990) 536-541
7. Hoelzer D., and Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go?. Semin Oncol 27 (2000) 540-559
8. Hegde U., Filie A., Little R.F., Janik J.E., Grant N., Steinberg S.M., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105 (2005) 496-502
9. Bromberg J.E.C., Breems D.A., Kraan J., Bikker G., van der Holt B., Smitt P.S., et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 68 (2007) 1674-1679
10. Brem S.S., Bierman P.J., Black P., Brem H., Chamberlain M.C., Chiocca E.A., et al. Central nervous system cancers. J Natl Compr Canc Netw 6 (2008) 456-504
11. Rhodes C.H., Glantz M.J., Glantz L., Lekos A., Sorenson G.D., Honsinger C., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77 (1996) 543-548
12. Gleissner B., Siehl J., Korfel A., Reinhardt R., and Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58 (2002) 390-396
13. Bhojwani D., and Pui C.H. Intrathecal liposomal cytarabine: more friend than foe?. Leuk Lymphoma 49 (2008) 1427-1430
14. Mahmoud H.H., Rivera G.K., Hancock M.L., Krance R.A., Kun L.E., Behm F.G., et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med 329 (1993) 314-319
15. Smith M., Arthur D., Camitta B., Carroll A.J., Crist W., Gaynon P., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14 (1996) 18-24
16. Burger B., Zimmermann M., Mann G., Kühl J., Löning L., Riehm H., et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 21 (2003) 184-188
17. Gilchrist G.S., Tubergen D.G., Sather H.N., et al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Childrens Cancer Group report. J Clin Oncol 12 (1994) 2594-2600
18. te Loo D.M., Kamps W.A., van der Does-van den Berg A., van Wering E.R., and de Graaf S.S. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol 24 (2006) 2332-2336
19. van den Berg H., Vet R., den Ouden E., and Behrendt H. Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone. Med Pediatr Oncol 25 (1995) 22-27
20. Gajjar A., Harrison P.L., Sandlund J.T., Rivera G.K., Ribeiro R.C., Rubnitz J.E., et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 96 (2000) 3381-3384
21. Pui C.H., Campana D., Pei D., et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360 (2009) (in press)
22. Howard S.C., Gajjar A.J., Cheng C., Kritchevsky S.B., Somes G.W., Harrison P.L., et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 288 (2002) 2001-2007
23. Conter V., Schrappe M., Aricü M., Reiter A., Rizzari C., Dördelmann M., et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC and good response to prednisone. J Clin Oncol 15 (1997) 2786-2791
24. Goldberg J.M., Silverman L.B., Levy D.E., Dalton V.K., Gelber R.D., Lehmann L., et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21 (2003) 3616-3622
25. Schrappe M., Reiter A., Ludwig W.D., Harbott J., Zimmermann M., Hiddemann W., et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95 (2000) 3310-3322
26. Rocha J.C., Cheng C., Liu W., Kishi S., Das S., Cook E.H., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005) 4752-4758
27. Krajinovic M., Costea I., and Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359 (2002) 1033-1034
28. Cario G., Izraeli S., Teichert A., Rhein P., Skokowa J., Möricke A., et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol 25 (2007) 4813-4820
29. Wu S., Burmeister T., Baldus C., Schwartz S., Notter M., Goekbuget N., et al. Low expression of IL-15 in adult B-lineage acute lymphoblastic leukemia is associated with central nervous system involvement at initial presentation [abstract 2389]. Blood (2007) 110
30. Cortes J., O'Brien S.M., Pierce S., Keating M.J., Freireich E.J., and Kantarjian H.M. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86 (1995) 2091-2097
31. Lazarus H.M., Richards S.M., Chopra R., Litzow M.R., Burnett A.K., Wiernik P.H., et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 108 (2006) 465-472
32. Fière D., Lepage E., Sebban C., Boucheix C., Gisselbrecht C., Vernant J.P., et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 11 (1993) 1990-2001
33. Kantarjian H.M., O'Brien S., Smith T.L., Cortes J., Giles F.J., Beran M., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 (2000) 547-561
34. Petersdorf S.H., Kopecky K.J., Head D.R., Boldt D.H., Balcerzak S.P., Wun T., et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group study. Leukemia 15 (2001) 208-216
35. Kantarjian H.M., Walters R.S., Smith T.L., Keating M.J., Barlogie B., McCredie K.B., et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72 (1998) 1784-1789
36. Hoelzer D., Ludwig W.D., Thiel E., Gassmann W., Löffler H., Fonatsch C., et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87 (1996) 495-508
37. Sancho J.M., Ribera J.M., Oriol A., Hernandez-Rivas J.M., Rivas C., Bethencourt C., et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 106 (2006) 2540-2546
38. Bostrom B.C., Sensel M.R., Sather H.N., Gaynon P.S., La M.K., Johnston K., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
39. Mitchell C.D., Richards S.M., Kinsey S.E., Lilleyman J., Vora A., and Eden T.O. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (2005) 734-745
40. Meikle A.W., and Tyler F.H. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 63 (1997) 200-207
41. Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., and Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5 (1987) 202-207
42. Igarashi S., Manabe A., Ohara A., Kumagai M., Saito T., Okimoto Y., et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. J Clin Oncol 23 (2005) 6489-6498
43. Clarke M., Gaynon P., Hann I., Harrison G., Masera G., Peto R., et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 21 (2003) 1798-1809
44. Pui C.H., Relling M.V., and Evans W.E. Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leuk Lymphoma 47 (2006) 2431-2432
45. Moghrabi A., Levy D.E., Asselin B., Barr R., Clavell L., Hurwitz C., et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109 (2007) 896-904
46. Stork L.C., Sather H., and Hutchinson R. Comparison of mercaptopurine (mp) with thioguanine (tg) and it methotrexate with it "triples" (itt) in children with sr-all: results of ccg1952 [abstract 585]. Blood 100 (2002) 156a
47. Vora A., Mitchell C.D., Lennard L., Eden T.O., Kinsey S.E., Lilleyman J., et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 (2006) 1339-1348
48. Jacobs S.S., Stork L.C., Bostrom B.C., Hutchinson R., Holcenberg J., Reaman G.H., et al., Children's Oncology Group; National Cancer Institute. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer 49 (2007) 250-255
49. Matloub Y., Lindemulder S., Gaynon P.S., Sather H., La M., Broxson E., et al., Children's Oncology Group. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 108 (2006) 1165-1173
50. Rubnitz J., Razzouk B., Bowman P., Dahl G., Lacayo N., Taub J., et al. Improved remission induction rate of childhood AML: preliminary results of the AML02 trial [abstract 275]. Blood 106 part 1 of 2 (2005) 84a
51. Blaney S.M., Poplack D.G., Godwin K., McCully C.L., Murphy R., and Balis F.M. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol 13 (1995) 177-179
52. Armon C., and Evans R.W. Addendum to assessment: prevention of post-lumbar puncture headaches: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 65 (2005) 510-512
53. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 352 (2005) 1791-1798
54. Baxter A.L., Fisher R.G., Burke B.L., Goldblatt S.S., Isaacman D.J., and Lawson M.L. Local anesthetic and stylet styles: factors associated with resident lumbar puncture success. Pediatrics 117 (2006) 876-881
55. Pui C.H., Cheng C., Leung W., Rai S.N., Rivera G.K., Sandlund J.T., et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 (2003) 640-649
56. Barredo J.C., Devidas M., Lauer S.J., Billett A., Marymont M., Pullen J., et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. J Clin Oncol 24 (2006) 3142-3149
57. Surapaneni U.R., Cortes J.E., Thomas D., O'Brien S., Giles F.J., Koller C., et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 94 (2002) 773-779
58. Fielding A.K., Richards S.M., Chopra R., Lazarus H.M., Litzow M.R., Buck G., et al., Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109 (2007) 944-950
59. Patte C., Auperin A., Michon J., Behrendt H., Leverger G., Frappaz D., et al., Société Française d'Oncologie Pédiatrique. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97 (2001) 3370-3379
60. Woessmann W., Seidemann K., Mann G., Zimmermann M., Burkhardt B., Oschlies I., et al., BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105 (2005) 948-958
61. Bomgaars L., Geyer J.R., Franklin J., Dahl G., Park J., Winick N.J., et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22 (2004) 3916-3921
62. Rueda Dominguez A., Olmos Hidalgo D., Viciana Garrido R., and Torres Sanchez E. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol 7 (2005) 232-238
63. Kim S., Khatibi S., Howell S.B., McCully C., Balis F.M., and Poplack D.G. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res 53 (1993) 1596-1598
64. Chamberlain M.C., Kormanik P., Howell S.B., and Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 52 (1995) 912-917
65. Glantz M.J., LaFollette S., Jaeckle K.A., Shapiro W., Swinnen L., Rozental J.R., et al. Randomized trial of a slow release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17 (1999) 3110-3116
66. Jaeckle K.A., Phuphanich S., Bent M.J., Aiken R., Batchelor T., Campbell T., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 84 (2001) 157-163
67. Jabbour E., O'Brien S., Kantarjian H., Garcia-Manero G., Ferrajoli A., Ravandi F., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109 (2007) 3214-3218
68. Benesch M., Sovinz P., Krammer B., Lackner H., Mann G., Schwinger W., et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 29 (2007) 222-226
69. McClune B., Buadi F.K., Aslam N., and Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 48 (2007) 1849-1851
70. Parasole R., Menna G., Marra N., Petruzziello F., Locatelli F., Mangione A., et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leuk Lymphoma 49 (2008) 1553-1559
71. Heideman R.L., Cole D.E., Balis F., Sato J., Reaman G.H., Packer R.J., et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49 (1989) 736-741
72. Fisher P.G., Kadan-Lottick N.S., and Korones D.N. Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 24 (2002) 274-278
73. Hoelzer D., and Gokbuget N. Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 15 (2002) 713-728
74. Bishop P.C., Wilson W.H., Pearson D., Janik J., Jaffe E.S., and Elwood P.C. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 17 (1999) 2479-2485
75. Hollender A., Kvaloy S., Nome O., Skovlund E., Lote K., and Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 13 (2002) 1099-1107
76. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 131 (2005) 13-21
77. Aviles A., Delgado S., Nambo M.J., Neri N., Murillo E., and Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology 69 (2005) 256-260
78. Zucca E., Conconi A., Mughal T.I., Sarris A.H., Seymour J.F., Vitolo U., et al., International Extranodal Lymphoma Study Group. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21 (2003) 20-27
79. Hormigo A., Abrey L., Heinemann M.H., and DeAngelis L.M. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126 (2004) 202-208
80. Montserrat E., Bosch F., Lopez-Guillermo A., et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 14 (1996) 941-944
81. Oinonen R., Franssila K., and Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 78 (1999) 145-149
82. Jahnke K., Thiel E., Martus P., Herrlinger U., Weller M., Fischer L., et al., German Primary Central Nervous System Lymphoma Study Group. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80 (2006) 159-165
83. Feugier P., Virion J.M., Tilly H., Haioun C., Marit G., Macro M., et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15 (2004) 129-133
84. van Besien K., Ha C.S., Murphy S., McLaughlin P., Rodriguez A., Amin K., et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91 (1998) 1178-1184
85. Colocci N., Glantz M., and Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol 24 (2004) 395-404
86. Bollen E.L., Brouwer R.E., Hamers S., Hermans J., Kluin M., Sankatsing S.U., et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 54 (1997) 854-859
87. Tomita N., Kodama F., Sakai R., Koharasawa H., Hattori M., Taguchi J., et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 38 (2000) 335-343
88. Keldsen N., Michalski W., Bentzen S.M., Hansen K.B., and Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma-a multivariate analysis. Acta Oncol 35 (1996) 703-708
89. Haioun C., Besson C., Lepage E., Thieblemont C., Simon D., Rose C., et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 11 (2000) 685-690
90. Boehme V., Zeynalova S., Kloess M., Loeffler M., Kaiser U., Pfreundschuh M., et al., German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 18 (2007) 149-157
91. Tilly H., Lepage E., Coiffier B., Blanc M., Herbrecht R., Bosly A., et al., Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102 (2003) 4284-4289
92. Bokstein F., Lossos A., Lossos I.S., and Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43 (2002) 587-593
93. Hill Q.A., and Owen R.G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20 (2006) 319-332
94. Jahnke K., Thiel E., Martus P., Schwartz S., and Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85 (2006) 45-50
95. Kasamon Y.L., Jones R.J., Piantadosi S., Ambinder R.F., Abrams R.A., Borowitz M.J., et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 11 (2005) 93-100
96. Alvarnas J.C., Negrin R.S., Horning S.J., Hu W.W., Long G.D., Schriber J.R., et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6 (2000) 352-358
97. Williams C.D., Pearce R., Taghipour G., Green E.S., Philip T., and Goldstone A.H. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome-a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 12 (1994) 2415-2422
98. Fischer L., Korfel A., and Lupp V. Kombinierte systemische und intrathekale Chemotherapie mit nachfolgender Hochdosischemotherapie und autologer Stammzelltransplantation bei ZNS-Rezidiven aggressiver Lymphome. http://www.lymphome.de/Gruppen/G-PCNSL-SG/Protokolle/NHL-ZNS-Rezidiv/index.jsp (home page of the German Competence Network Malignant Lymphomas); 2007
99. Fischer L., Korfel A., Jahnke K., Kiewe P., and Thiel E. High-dose methotrexate and ifosfamide for CNS relapse of aggressive lymphoma [abstract 12524]. J Clin Oncol 25 (2007) 606s
100. MacKintosh F.R., Colby T.V., Podolsky W.J., Burke J.S., Hoppe R.T., Rosenfelt F.P., et al. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer 49 (1982) 586-595
101. Bashir R.M., Bierman P.J., Vose J.M., Weisenburger D.D., and Armitage J.O. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 14 (1991) 478-482
102. Zinzani P.L., Magagnoli M., Frezza G., Prologo G., Gherlinzoni F., Bendandi M., et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 32 (1999) 571-576
103. Ersboll J., Schultz H.B., Thomsen B.L., Keiding N., and Nissen N.I. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 35 (1985) 487-496
104. Liang R., Chiu E., and Loke S.L. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 8 (1990) 141-145
105. Buckstein R., Lim W., Franssen E., and Imrie K.L. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma 44 (2003) 955-962
106. Cheung C.W., Burton C., Smith P., Linch D.C., Hoskin P.J., and Ardeshna K.M. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 131 (2005) 193-200
107. Bos G.M., van Putten W.L., van der Holt B., van den Bent M., Verdonck L.F., and Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?. Dutch HOVON Group. Ann Oncol 9 (1998) 191-194